Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Robinhood Markets, Inc. (HOOD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Robinhood Markets, Inc.Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Robinhood Markets, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Robinhood Markets, Inc. trades at $107.35 (market cap $89.13B), while Regeneron Pharmaceuticals Inc trades at $677.66 (market cap $70.47B). The key difference: Robinhood Markets, Inc. is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.

HOODREGN
Market Cap
$89.13B$70.47B
Sector
TechnologyHealth
52-Week High
$152.46$812.27
52-Week Low
$65.16$545.46
Enterprise Value
$90.33B$64.42B
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Robinhood Markets, Inc.

Robinhood Markets (HOOD) trades at $99.41, down 0.55% on the day, with technical indicators showing a bearish short-term trend. The stock has strong fundamentals, including 2025 revenue of $4.47 billion and net income of $1.88 billion, with a net margin of 42.09%. Recent news highlights institutional selling and CFO share disposals, but analyst consensus remains bullish with a $113.21 price target. Cash flow improved significantly in 2025 to $1.20 billion net.

The outlook for HOOD is mixed: strong profitability and growth support upside potential, but near-term technical weakness and insider selling pose risks. Investors should weigh robust financials against market sentiment and competitive pressures in the fintech sector.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.

Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN